Literature DB >> 11483900

Mersilene mesh sling: short- and long-term clinical and urodynamic outcomes.

S B Young1, A E Howard, S P Baker.   

Abstract

OBJECTIVE: We sought to determine the long-term efficacy, safety, and urodynamic effects of the Mersilene mesh suburethral sling in treating complicated forms of genuine stress incontinence. STUDY
DESIGN: Two hundred women diagnosed with genuine stress incontinence, complicated by recurrence, intrinsic sphincter deficiency, or chronically increased intraabdominal pressure underwent a suburethral mesh sling procedure (Mersilene; Ethicon Inc, Somerville, NJ). They were monitored with yearly clinical examinations plus short- and long-term postoperative urodynamic evaluations; statistical analysis was carried out by use of the Friedman 2-way analysis by rank, Fischer-Freeman-Halton exact testing, analysis of variance for repeated measures, Wilcoxon, exact Mann-Whitney U test, and Bonferroni paired t test. Of 176 patients who were 5 months or more postop, 127 (72%) had preoperative and short-term postoperative urodynamic evaluations (range 5 to 23 months, mean 12.6 months). Fifty-two of 117 women who were more than 19 months postop (44%) completed preoperative and long-term postoperative urodynamic evaluations at a mean of 63 months (range 20 to 107). One hundred thirty-six of 176 patients (77%) who were more than 4 months postop had a short- and/or long- term postoperative urodynamic evaluation (range 5 to 107 months, mean 30 months).
RESULTS: Objective cure rate by stress test was 93% (126 of 136 patients) at a mean of 30 months follow-up. The long-term objective cure rate was 94% (49 of 52). Subjectively, the short- and long-term cure rates were 95.3% and 90.4%, respectively. The cotton swab angle deflection decreased by a mean of 54 degrees at 1 year and 50 degrees at 5 years. Of the 10 failures, the mean preoperative cotton swab straining angle was 19.6 degrees, with 6 being < 30 degrees. Nineteen patients had a negative preoperative cotton swab angle test result (mean straining angle 15 degrees before operation, -6 degrees after operation) and a long-term cure rate of 67%. The objective cure rate in patients with positive cotton swab angle results monitored long term (mean 62 months) was 100% (41 of 41). The postvoid residual increased by a mean of 25 mL short term and 10 mL long term. Thirty-eight patients (19%) had a total of 43 complications. Seven patients (3.5%) had long-term retention. De novo detrusor instability occurred in 12 patients (8.8%), although it was cured in 6 (4.4%). Eight patients (4%) had vaginal or inguinal sling erosion and were healed after revision. Delayed healing at the vaginal sling site responded completely to estrogen cream in two (1%) patients. Five women had treatable vaginal stenosis, 5 had a local inguinal collection/infection unrelated to the mesh, and 3 required a 2-unit transfusion of packed red blood cells. One patient each had an entrapped nerve released, a cystotomy repaired, or experienced thigh numbness or groin pain.
CONCLUSIONS: The suburethral Mersilene mesh sling has a very high long-term objective and subjective cure rate in the treatment of complicated forms of genuine stress incontinence. Frequent complications do occur but are remediable. The 33% failure rate among patients with a preoperative negative cotton swab angle test result and the very low cotton swab straining angle among the 7% who had sling failures further confirms the widely held belief that sling urethropexy in the absence of hypermobility lacks efficacy.

Entities:  

Mesh:

Year:  2001        PMID: 11483900     DOI: 10.1067/mob.2001.116370

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Suburethral vaginal erosion and pyogenic granuloma formation: an unusual complication of intravaginal slingplasty (IVS).

Authors:  Y N Lim; A Rane
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-19

Review 2.  Pubovaginal sling materials and their outcomes.

Authors:  Ömer Bayrak; David Osborn; William Stuart Reynolds; Roger Roman Dmochowski
Journal:  Turk J Urol       Date:  2014-12

3.  A complex fistula caused by an eroding pelvic mesh sling.

Authors:  Ugo Ihedioha; E Leung; L Chung; G Burgess; D Hendry; P J O'dwyer
Journal:  Hernia       Date:  2006-09-23       Impact factor: 4.739

4.  Urodynamic changes after tension-free sling procedures: Mycromesh-Plus vs TVT sling.

Authors:  Hilary J Cholhan; Peter M Lotze
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-08-28

5.  Sling and bulking agent placement procedures.

Authors:  Alfred E Bent
Journal:  Rev Urol       Date:  2004

6.  A safety and quality of life analysis of intravaginal slingplasty in female stress incontinence: a prospective, open label, multicenter, and observational study.

Authors:  Joon Chul Kim; Byung Soo Chung; Jong Bo Choi; Ji Youl Lee; Kyu-Sung Lee; Won Hee Park; Myung-Soo Choo
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-02-28

Review 7.  Safety considerations for synthetic sling surgery.

Authors:  Jerry G Blaivas; Rajveer S Purohit; Matthew S Benedon; Gabriel Mekel; Michael Stern; Mubashir Billah; Kola Olugbade; Robert Bendavid; Vladimir Iakovlev
Journal:  Nat Rev Urol       Date:  2015-08-18       Impact factor: 14.432

8.  Postoperative erosions of the Mersilene suburethral sling mesh for antiincontinence surgery.

Authors:  Kyle J Wohlrab; Elisabeth A Erekson; Deborah L Myers
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-12-13

Review 9.  Biomaterials for pelvic floor reconstructive surgery: how can we do better?

Authors:  Giulia Gigliobianco; Sabiniano Roman Regueros; Nadir I Osman; Julio Bissoli; Anthony J Bullock; Chris R Chapple; Sheila MacNeil
Journal:  Biomed Res Int       Date:  2015-04-21       Impact factor: 3.411

10.  Complications of grafts used in female pelvic floor reconstruction: Mesh erosion and extrusion.

Authors:  Tanya M Nazemi; Kathleen C Kobashi
Journal:  Indian J Urol       Date:  2007-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.